Two-arm – Page 7 – Communicable Diseases Research

Nigella sativa supplementation to treat symptomatic mild COVID-19: A structured summary of a protocol for a randomised, controlled, clinical trial

Letter

Published on 2020-08-082022-10-29
Journal: Trials [Category] COVID-19, MERS,

Protecting Frontline Health Care Workers from COVID-19 with Hydroxychloroquine Pre-exposure Prophylaxis: A structured summary of a study protocol for a randomised placebo-controlled multisite trial in Toronto, Canada

Letter

Published on 2020-07-142022-10-29
Journal: Trials [Category] COVID-19, SARS,

[키워드] 1:1 Activation age All participants anticipated baseline blinded block sizes blocked blood sample Canada Chloroquine circulating cirrhosis clinical clinician composite endpoint computer-generated Concomitant medication correlation Course COVID-19 COVID-19 negative criteria deficiency determine diabete diagnostic disease severity dissemination ECG element Encephalopathy endothelial Enrollment extension FIVE fixed Follow-up G6PD HCQ HCW Health care worker Hepatitis high risk hospital Hospitalization Hospitalized Host Hydroxychloroquine immune include individually randomized insulin intensive care units Intervention intervention arm intubation investigator Laboratory Liver disease Long marker microbiologically Mortality multisite neutralize non-invasive ventilation non-specific number objective offered Older open label Oropharyngeal outcome outcome measure parallel-group participant patients per day Placebo placebo-controlled plasma porphyria positive positive result pregnant Prevent Primary outcome Prophylaxis Protecting protocol Psychological distress psychological Impact QTc QTc interval randomised randomised placebo controlled trial reactive reduce Registered renal reported Research Respiratory failure risk of COVID-19 Sample size SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 virus secondary Seroconversion serology Standard status study period Study protocol Support symptom duration symptomatic syndrome Tablet tablets term Toronto Trial two group Two-arm undergo use of hydroxychloroquine ventilator viral PCR Viral RNA website worker
[DOI] 10.1186/s13063-020-04577-8 PMC 바로가기 [Article Type] Letter

Impact of vitamins A, B, C, D, and E supplementation on improvement and mortality rate in ICU patients with coronavirus-19: a structured summary of a study protocol for a randomized controlled trial

Study Protocol

Published on 2020-07-062022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 Abnormalities absence Ascorbate assigned baseline Biotin block BMI body temperature Chemotherapy clinical clinical trial clinical trials Complete condition control group COVID-19 CRP CT scan definitive diagnosis dissemination Duration element eligible patient ESR evaluate exclusion criteria expected female patient Folic acid Gender HIV Hospitalization Hypothesis ICU ICU patient IL6 Imam Impact IMPROVE include inclusion criteria intensive care unit Intervention invasive Iran kidneys liver lung male mortality rate New nicotinamide Non-invasive number objective organ outcome oxygen saturation pantothenate parallel group participant participated Patient patients patients with COVID-19 PCR per day percentage phosphate Placebo polymerase chain protocol pulmonary involvement randomization Randomized Randomized controlled trial Randomly receive registry renal researcher respiratory Riboflavin Sample size severity significantly sodium SpO2 Study protocol Supplementation Support table Tehran the patient thiamine nitrate TNF-α Treatment Two-arm viral disease Vitamin vitamin A Vitamin B Vitamin C Vitamin D Vitamin E WBC website weight with COVID-19
[DOI] 10.1186/s13063-020-04547-0 PMC 바로가기 [Article Type] Study Protocol

Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial

Letter

Published on 2020-07-022022-10-29
Journal: Trials [Category] COVID-19, SARS,

[키워드] 1:1 aetiology agreement allocation Anosmia anticipated Arm ARMS Asymptomatic automatically Barcelona blinded block randomization Cardiac pathology change characterized chills clinical Clinical course clinical trial close contact collected Compound Concomitant conducted confirmed COVID-19 case Contact cough Course COVID-19 COVID-19 disease COVID-19 disease severity CRF criteria delivery determine diarrhoea dissemination double-blind Dyspnoea ECDC Effect Efficacy Efficacy and safety element EudraCT evaluate evaluate the effect Fever FIVE gestation global health HCQ headache history hospital Hospitalization Hydroxychloroquine hypersensitivity inclusion criteria intervention study investigator Liver disease Mild mild symptoms Mortality multicentre nasopharyngeal number objective oropharyngeal swab outcome packaged Pain participant Patient PCR PCR-confirmed Placebo placebo controlled trial placebo-controlled Pregnancy pregnant pregnant women prenatal Prevent Primary outcome progression protocol randomised randomised controlled trial Randomized receive recruited recruitment reducing Registered risk Sample size SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 PCR SARS-CoV-2 viral shedding status stratified study group study participant Study protocol subsequent Symptom symptomatic syndrome Tablet Tolerability Transmission Treatment treatment group Trial Two-arm uterine website women
[DOI] 10.1186/s13063-020-04557-y PMC 바로가기 [Article Type] Letter

Impact of pantoprazole on absorption and disposition of hydroxychloroquine, a drug used in Corona Virus Disease-19 (Covid-19): A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-292022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 Absorption administration All participant anticipated Area assigned AUC C max center changes in clinical Concentration control group Corona Course COVID-19 CYP2D6 CYP3A4 dissemination dose drug drug-drug interaction element enrolment enzyme activity Enzymes EudraCT Germany HCQ Hydroxychloroquine Impact inhibitor investigator Microdosing Midazolam mononuclear cell not blinded number objective Open-label outcome P450 Pantoprazole parallel group participant Patient PBMC PBMCs performed Peripheral blood Phase I plasma PPI probe protocol randomisation list randomised randomised controlled trial Randomized receive recruitment Registered registry reported Sample size secondary single dose Standard status Study protocol target cell treated treatment group Trial trial protocol Two-arm university Volunteer website Whole blood Yohimbine
[DOI] 10.1186/s13063-020-04476-y PMC 바로가기 [Article Type] Letter

Effect of hydroxychloroquine on COVID-19 prevention in cancer patients undergoing treatment: a structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-262022-10-29
Journal: Trials [Category] COVID-19, SARS,

[키워드] 1:1 Acute Lymphoid Leukemia acute myeloid leukemia age anticipated approval approved assigned blinded blocks Breast cancer calculated Cancer cancer patient cardiac disease chemotherapeutic agent chronic pulmonary disease clinical Colon cancer company Computed tomography control group cough COVID-19 COVID-19 symptom curative intent data analyst disease dissemination Effect element examined exclusion criteria Fever FIVE follow-up period High-resolution Hydroxychloroquine IgG antibody incidence of COVID-19 include Intervention investigated Iran leukemia Lungs lymphoid lymphoma Mashhad Medical Sciences novel nucleic acid amplification number objective occur outcome parallel-group participant Patient patients performed pharmaceutical Placebo primary end point produced Prophylaxis protocol randomised randomised controlled trial randomization sequence Randomly randomly permuted blocks recruitment Registered registration date registry respiratory tract infection Sample size sensitivity Shortness of breath specific IgM status Study protocol Symptom Tablet the patient the SARS-CoV-2 virus total sample size treated Treatment Trial triple-blind two group Two-arm university website
[DOI] 10.1186/s13063-020-04485-x PMC 바로가기 [Article Type] Letter

Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-052022-10-29
Journal: Trials [Category] COVID-19, SARS,

[키워드] 1:1 7-point ordinal scale accelerate activities activity acute respiratory syndrome adaptive addition administration Admission airway Akershus allocation sequence Analysis anticipated approach automatically baseline Biochemistry Biomarker blinded Blinding Blood C-reactive protein cardiac troponin Chloroquine clinical Clinical outcome Clinical practice clinical status clinical symptom collected condition coronavirus coronavirus disease COVID-19 Culture database Department disease dissemination early treatment element Endpoint examined excluded extracorporeal membrane oxygenation Good harmonization hepatic injury history hospital Hospital admission hospitalisation hospitalised hospitalised patient Hospitalized Hydroxychloroquine Hypothesis In-hospital include independent Inpatient intensive care intensive care unit International Conference Intervention intervention arm Invasive mechanical ventilation Laboratory marker Microbiology Mortality nasopharyngeal NEWS2 non-invasive ventilation Norway number Nurse objective open label Oropharyngeal Oropharyngeal sampling outcome oxygen participant Patient patients peptide Placebo polymerase chain polymerase chain reaction positive Practice Pragmatic pragmatic trial primary endpoint profile Prolonged Protein protocol QT interval randomisation randomised randomised controlled randomised controlled trial randomization Randomized Randomized controlled trial recruited recruitment Registered renal requiring supplemental oxygen resource responsible RT-PCR Safe Sample size SARS-CoV-2 SARS-CoV-2 viral load score secondary Seven standard care statistical analyses status Study protocol subjects Surveillance therapy transcriptase Treatment treatment allocation Trial Two-arm university use of hydroxychloroquine Viral load virological clearance viruses vital signs website
[DOI] 10.1186/s13063-020-04420-0 PMC 바로가기 [Article Type] Letter

Prevalence of Alcohol and Tobacco Use in India and Implications for COVID-19 – Niyantrita Madhumeha Bharata Study Projections

Original Article

Published on 2020-01-012022-10-29
Journal: Journal of Medicine and Life [Category] COVID-19, SARS,